|
|
|
|
|
| 1984 | Sunaka’ predecessor company, Triton Laboratories, was established. Triton commenced manufacturing Paracetamol API at Bonthapally on the outskirts of Hyderabad |
| 1987 | Triton became one of the first Indian pharmaceutical companies to export pharmaceutical products to the U.S. |
| 1990 | The Company opened its second manufacturing facility at Jeedimetla to produce multiple APIs |
|
|
|
|
| 1991 | Sunaka was incorporated and served as a trading Company |
| 1994 | Sunaka set up a PFI facility at Jeedimetla |
| 1995 | Sunaka conducted its Initial Public Offering (IPO) |
|
|
|
|
| 2003 | Sunaka opened a 7,200 MTPA PFI facility at Gagillapur, the largest-PFI facility in the world |
| 2006 | Sunaka built a new state-of-the-art Paracetamol API facility at Bonthapally to meet increased demand from the regulated markets |
| 2007 | Sunaka established Sunaka-Biocause, a JV with Hubei Biocause Pharmaceutical, a premier Ibuprofen manufacturer |
| 2008 | Sunaka forward integrated and commenced operations at its Finished Dosage facility at Gagillapur |
| 2010 | Sunaka received U.S. FDA approval for its first Abbreviated New Drug Application (ANDA) |
|
|
|
|
| 2011 | Sunaka established Sunaka-OmniChem, a JV with Ajinomoto OmniChem. The business focuses on the CRAMS space | | | | 2013 | Sunaka completed a major expansion at its Gagillapur facility. | | | | 2013 | Sunaka acquired Auctus Pharma. | | |
|
|
|
|
|
|
|
